Ide, MF; Dittmar, M; Wurm, M et al.
Specific genotype variations of Interleukin-10.G (IL-10.G) and MHC class I chain-related gene A (MICA) short tandem repeat polymorphisms in thyroid autoimmunityExp Clin Endocr Diab. H. S!. 2006 S. P12
Wehler, T; Wolfert, F; Schimanski, CC et al.
Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease.Oncol Rep. Bd. 16. H. 6. 2006 S. 1159-64
Kausche, S; Wehler, T; Schnürer, E et al.
Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.Cancer Res. Bd. 66. H. 23. 2006 S. 11447-11454
Fottner, C; Helisch, A; Schreckenberger, M et al.
Superiority of 6-[18F]-Fluorodopamin Positron Emission Tomography (DOPA-PET) versus [123J]-Metaiodobenzylguanidine (MIBG) Scintigraphy in the localization of extraadrenal or multifocal pheochromocytomas and paragangliomoas. 50th Annual Meeting of the German Society of EndocrinologyExp Clin Endocr Diab. Bd. 114. 2006 S. P01-002
Schulze-Bergkamen, H; Fleischer, B; Schuchmann, M et al.
Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.BMC Cancer. Bd. 6. 2006 S. 232
Fottner, C; Helisch, A; Minnemann, T et al.
Targeted peptide receptor radionuclide for advanced neuroendocrine tumors (NET) with 90 Y-DOTATOC - tumor response and clinical benefit. 50th Annual Meeting of the German Society of EndocrinologyExp Diabesity Res. Bd. 114. 2006 S. P05-069
Müller, M; Meyer, M; Schilling, T et al.
Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.Int J Oncol. Bd. 29. H. 4. 2006 S. 973-80
Becker, CH; Fantini, MC; Neurath, MF
TGF-beta as a T cell regulator in colitis and colon cancer.Cytokine Growth Factor Rev. Bd. 17. H. 1-2. 2006 S. 97-106
Neurath, Markus F.; Finotto, Susetta
The many roads to inflammatory bowel diseasesImmunity. Bd. 25. H. 2. Cambridge, Mass.: Cell Press 2006 S. 189 - 191
Strub, A; Ulrich, WR; Hesslinger, C et al.
The novel imidazopyridine 2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase.Mol Pharmacol. Bd. 69. H. 1. 2006 S. 328-337